India Immunology Drugs Market By Drug Class (Monoclonal Antibodies (mAb), Antibody Drug Conjugates, Interferon and Cytokine therapies, Immunosuppressive medication, Others), By Indication (Arthritis, Plaque Psoriasis, Spondylitis, Inflammatory Bowel Disease, Transplant Rejection, Others), By End User (Hospitals & Clinics, Cancer Research Institute, Others), By Region, Competition, Forecast & Opportunities, 2021-2031F

Key Insights	Details
Forecast Period	2027-2031
Market Size (2025)	USD 4.65 Billion
CAGR (2026-2031)	7.08%
Fastest Growing Segment	Monoclonal Antibodies (mAb)
Largest Market	North
Market Size (2031)	USD 7.01 Billion

Market Overview

The India Immunology Drugs Market is expected to grow from USD 4.65 Billion in 2025 to USD 7.01 Billion by 2031 at a 7.08% CAGR. The India Immunology Drugs Market comprises therapeutic agents designed to modulate the immune system, employed in managing autoimmune diseases, inflammatory conditions, and various cancers. Market growth is primarily driven by the increasing prevalence of autoimmune and chronic inflammatory disorders, coupled with expanding healthcare expenditure and improved diagnostic capabilities nationwide. According to the Pharmaceuticals Export Promotion Council of India, drug formulations and biologicals, a category significantly encompassing immunology drugs, constituted 75.74 percent of India's total pharmaceutical exports during May 2025-26.

A notable challenge potentially impeding market expansion is the considerable cost associated with advanced biologic therapies. This can restrict widespread patient access and affordability, particularly within India's heterogeneous healthcare infrastructure, despite growing demand for innovative treatments.

Key Market Drivers

Rising Burden of Immunological Disorders Drives Market Demand
The rising prevalence of immunological disorders represents a primary catalyst for the expansion of the India Immunology Drugs Market. These conditions, encompassing autoimmune diseases and inflammatory disorders, necessitate ongoing therapeutic interventions, thereby sustaining demand for immunology drugs. The increasing incidence of such diseases amplifies the patient pool requiring diagnosis and treatment. According to the Delhi Rheumatology Association Update 2025, published in March 2025 by Fortis Healthcare, rheumatological diseases are affecting approximately 25% of the Indian population. This significant demographic burden underscores the critical need for advanced immunological therapies, driving pharmaceutical companies to enhance their research and development efforts and expand their product portfolios to address unmet medical needs across the country.

Biosimilars Expand Access and Support Market Growth
The increasing adoption and accessibility of biosimilars further stimulate growth within the market, primarily by enhancing affordability and broadening patient reach for advanced treatments. Biosimilars offer cost-effective alternatives to expensive biologic drugs, alleviating some of the financial burden on patients and healthcare systems. This improved affordability facilitates wider access, particularly in a diverse healthcare landscape like India. According to news from Zydus Lifesciences, in January 2026, the company launched Tishtha™, India's first biosimilar of Nivolumab, priced at approximately one-fourth the cost of the reference drug. Such initiatives are pivotal in democratizing access to complex treatments. Furthermore, the overall Indian domestic pharmaceutical market, which includes immunology drugs, was valued at approximately US$ 60 billion in FY26, according to the Indian Brand Equity Foundation (IBEF), referencing a March 2026 Press Information Bureau release. This robust market size provides a conducive environment for biosimilar growth and overall immunology drug market expansion.

Download Free Sample Report

Key Market Challenges

High costs constrain access and widen affordability gaps.
The considerable cost associated with advanced biologic therapies represents a significant challenging factor for the India Immunology Drugs Market. This high expense directly constrains the widespread availability of innovative treatments, as a notable portion of the population faces considerable affordability hurdles. India's diverse healthcare infrastructure further accentuates these access disparities for critical medications.

Out-of-pocket burden and pricing measures hinder uptake and market growth.
The substantial financial burden imposed by these therapies often results in elevated out-of-pocket expenses for patients, hindering their ability to initiate or sustain necessary treatment. This restricted patient access directly impedes the overall growth trajectory of the immunology drugs market. According to the Indian Pharmaceutical Alliance (IPA), in October 2026, the government's decision to cap trade margins on non-scheduled anti-cancer drugs at 30 percent was welcomed, with the potential for price reductions of up to 70 percent in certain cases. While this measure specifically targets cancer medications, it underscores the systemic challenge of high-cost advanced therapies in India and the direct impact of price on patient affordability and market penetration for such critical treatments, including immunology drugs.

Key Market Trends

Shift Toward Biologics and Targeted Therapies
The India Immunology Drugs Market is significantly influenced by a paradigm shift towards biologics and advanced targeted therapies. These innovative treatments offer enhanced specificity and efficacy compared to traditional small molecule drugs, addressing complex autoimmune and inflammatory conditions with greater precision. This trend is driven by ongoing research and development efforts, leading to the introduction of novel therapeutic agents that provide improved patient outcomes and address previously unmet medical needs. For example, the market is witnessing increased uptake of monoclonal antibodies and fusion proteins designed to modulate specific immune pathways, signifying a move up the value chain. According to The Pharma India in August 2026, Sun Pharma invested ₹3,474.1 crore in research and development during FY2025-26, highlighting a concentrated effort towards advancing innovative therapies within its specialty portfolio.

Expansion of Domestic Biologics Manufacturing and R&D Capabilities
Another pivotal trend shaping the India Immunology Drugs Market is the substantial growth in domestic biologics manufacturing and research capabilities. This localized development is crucial for reducing reliance on imports, fostering self-sufficiency, and potentially lowering treatment costs over the long term, thereby expanding patient access. Indian pharmaceutical companies are increasingly investing in sophisticated infrastructure and expertise for the production of complex biological molecules, from active pharmaceutical ingredients to finished drug products. This includes the establishment of advanced bioprocessing facilities and dedicated R&D centers. According to a press release from Biological E. Limited in December 2025, the company signed a Memorandum of Understanding with the Government of Telangana to invest ₹4,000 crore towards expanding its manufacturing capabilities.

Segmental Insights

Growth Drivers for Monoclonal Antibodies in India
In the India Immunology Drugs Market, Monoclonal Antibodies (mAbs) represent the fastest-growing segment, driven by the increasing prevalence of chronic conditions such as cancer and autoimmune disorders across the country. This rapid expansion is further propelled by significant advancements in biotechnology, leading to more targeted and effective therapies. The growing adoption of biosimilars, often developed by Indian pharmaceutical companies, also enhances affordability and accessibility, supported by government initiatives and evolving regulatory frameworks under bodies like the Central Drugs Standard Control Organization (CDSCO). Moreover, expanding healthcare infrastructure and rising healthcare expenditure contribute to the wider integration of these advanced treatments into patient care.

Regional Insights

Robust Healthcare Infrastructure and Autoimmune-Disease Burden Drive North India's Immunology Drug Market Leadership
North India holds a dominant position in the India Immunology Drugs Market, primarily driven by its robust healthcare infrastructure. The region boasts state-of-the-art medical facilities and a highly skilled workforce, ensuring efficient delivery of specialized immunology treatments and comprehensive patient care. This is crucial given the high prevalence of autoimmune diseases, including rheumatoid arthritis, lupus, and psoriasis, which significantly contributes to the demand for advanced immunology drugs in the region. Furthermore, North India's leading healthcare institutions are at the forefront of research and treatment for these complex conditions, attracting patients seeking specialized therapies. An efficient transportation network also supports the smooth distribution of these essential drugs, solidifying the region's market leadership.

Recent Developments

• In December 2025, Sun Pharmaceutical Industries Ltd. launched ILUMYA (Tildrakizumab) in the Indian market, offering a novel biologic treatment for adults with moderate-to-severe plaque psoriasis. This innovative drug is an interleukin-23 (IL-23) inhibitor, providing a new therapeutic option for patients suffering from this chronic autoimmune condition. The introduction of ILUMYA underscored Sun Pharma's commitment to bringing advanced global innovative medicines to India, aiming to improve long-term skin clearance and enhance the quality of life for patients.
• In September 2024, Indian Immunologicals Limited (IIL) announced the launch of Havisure (0.5 ml), India's first indigenously developed pediatric dose of Hepatitis A vaccine. This significant product introduction aimed to provide an affordable and effective vaccination option, particularly for children, addressing a key public health need in the country. The launch reinforced IIL's commitment to self-sufficiency in vaccine production and contributed to expanding the immunology drug landscape in India. Havisure is available in both pediatric and adult dosages, representing a substantial advancement in preventive immunology.
• In July 2024, Zydus Lifesciences received regulatory approval in India for its nivolumab biosimilar, ZRC-3276. This approval marked a significant milestone as it was the first nivolumab biosimilar in the world to gain regulatory clearance, positioning Zydus to eventually offer a more accessible immuno-oncology treatment. Nivolumab targets the PD-1 receptor on T-cells, enhancing the immune system's response against various cancers such as melanoma and non-small cell lung cancer. This development showcased substantial progress in the research and development capabilities of Indian pharmaceutical companies in the immunology drugs market.
• In March 2024, Dr. Reddy's Laboratories formed an exclusive partnership with Sanofi Healthcare India Private Limited to manage the distribution of Sanofi's vaccine portfolio across India. This collaboration encompassed several pediatric and adult vaccine brands, including Hexaxim, Pentaxim, Tetraxim, and FluQuadri. Sanofi maintained ownership and responsibility for manufacturing and importing the vaccines into India. This strategic alliance aimed to expand the reach of these crucial immunology-related products within the Indian market by leveraging Dr. Reddy's distribution capabilities, thereby enhancing vaccination coverage.

Key Market Players

• Panacea Biotec Ltd.
• Bristol-Myers Squibb India Pvt Ltd.
• Wockhardt Ltd.
• Pfizer Ltd.
• Sanofi India Ltd.
• GlaxoSmithKline Pharmaceuticals Ltd.
• Abbott India Ltd.
• Genetech Pvt Ltd.
• Novartis India Ltd.
• Allergan India Pvt Ltd.

By Drug Class	By Indication	By End User	By Region
Monoclonal Antibodies (mAb) Antibody Drug Conjugates Interferon and Cytokine therapies Immunosuppressive medication Others	Arthritis Plaque Psoriasis Spondylitis Inflammatory Bowel Disease Transplant Rejection Others	Hospitals & Clinics Cancer Research Institute Others	North India East India West India South India

Report Scope:

In this report, the India Immunology Drugs Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• India Immunology Drugs Market, By Drug Class:

• Monoclonal Antibodies (mAb)
• Antibody Drug Conjugates
• Interferon and Cytokine therapies
• Immunosuppressive medication
• Others

• India Immunology Drugs Market, By Indication:

• Arthritis
• Plaque Psoriasis
• Spondylitis
• Inflammatory Bowel Disease
• Transplant Rejection
• Others

• India Immunology Drugs Market, By End User:

• Hospitals & Clinics
• Cancer Research Institute
• Others

• India Immunology Drugs Market, By Region:

• North India
• East India
• West India
• South India